SLE
Clinical trials for SLE explained in plain language.
Never miss a new study
Get alerted when new SLE trials appear
Sign up with your email to follow new studies for SLE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a One-Time cell treatment tame lupus in young patients?
Disease control Recruiting nowThis study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't improved with standard treatments. CART19 uses a patient's own immune cells, modified in a lab to target and calm the overactive immune system causing lupus. The g…
Matched conditions: SLE
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New lupus drug CLN-978 enters early human testing
Disease control Recruiting nowThis early-stage study tests a new drug called CLN-978 in 24 people with moderate to severe lupus. The main goal is to see if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body and how it affects immune cells. This is a first step to…
Matched conditions: SLE
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New antibody drug takes aim at autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…
Matched conditions: SLE
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pill VENT-03 aims to calm lupus skin flares
Disease control Recruiting nowThis study tests an experimental tablet called VENT-03 for people with active cutaneous lupus erythematosus (CLE), a condition causing painful skin rashes. Twenty-four adults will take either VENT-03 or a placebo for 4 weeks, then everyone gets VENT-03 for 8 more weeks. Researche…
Matched conditions: SLE
Phase: PHASE2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immune reset: CAR-T therapy targets lupus, MS, and more
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…
Matched conditions: SLE
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New lupus pill enters human testing
Disease control Recruiting nowThis study tests a new drug called APG-2575 in 40 people with mild-to-moderate lupus. Participants take either the drug or a placebo daily for 12 weeks. The main goal is to check safety and how the body processes the drug, not yet to see if it improves lupus symptoms.
Matched conditions: SLE
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New lupus pill ONT01 enters human safety trials
Disease control Recruiting nowThis early-phase study tests whether a new drug called ONT01 is safe for people with lupus nephritis or systemic lupus erythematosus (SLE). About 61 participants will receive ONT01 alongside their usual lupus medications. The goal is to find the highest safe dose and see if it im…
Matched conditions: SLE
Phase: EARLY_PHASE1 • Sponsor: Hospital for Special Surgery, New York • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental CAR-T therapy takes on lupus and more
Disease control Recruiting nowThis early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…
Matched conditions: SLE
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Cord blood cells could tame lupus in first human test
Disease control Recruiting nowThis early-phase trial is testing whether a single injection of stem cells from donated umbilical cords is safe for people with active lupus. Ten adults will receive the cells alongside their usual care. Researchers will monitor side effects and check for signs that lupus activit…
Matched conditions: SLE
Phase: PHASE1 • Sponsor: LiveKidney.Bio • Aim: Disease control
Last updated Jun 26, 2026 16:22 UTC
-
Lupus may affect pregnancies years before diagnosis
Knowledge-focused Recruiting nowThis study looks at pregnancy outcomes in 50 women who had at least one pregnancy before being diagnosed with lupus. Researchers will collect data from medical records and interviews to see how often pregnancy complications occurred before the lupus diagnosis. The goal is to bett…
Matched conditions: SLE
Sponsor: University of Algiers • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC